arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

download Export Data

Oric Pharmaceuticals, Inc.

ORIC

$8.47 ▼ -0.88 (-9.46%) at close

9 Visible periods

18 Metrics

Peer-ranked Benchmarks

Price Chart

Health

Poor

Bearish

auto_awesome

Analytical Summary

Oric Pharmaceuticals, Inc. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $743.6M

Dividend Yield —

Revenue Growth —

Op. Margin —

ROIC -29.4% ↗

FCF / Share $-1.27 ↗

Trailing P/E —

Price / Book 2.2x

FCF Yield —

Debt / Equity —

info Valuation on last close. End-of-day price, Nov 5, 2026.

9-Year Financial Trajectory

Annual

Metric Value Trend Year over Year Percentile

Net Income Profit after all expenses

$-129.47M

↓ -1.3% —

FCF / Share Free cash flow per share

$-1.27

↑ +22.1% —

trending_up

Bullish Indicators

No bullish signals detected.

warning

Bearish Risks

Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns ↓

Cash Quality ↑

Financial view

Statement lens

Choose the reporting cadence, isolate a period range, or search directly for a metric.

Cadence

Annual Quarterly

Range

→

📈 Is growth accelerating? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗
EPS Growth YoY (%)	19.7% Good ↑ Good Improving Year-over-year change in earnings per share Optimal: > 10%	6.6% Fair ↑ Fair Improving Year-over-year change in earnings per share Optimal: > 10%	12.9% Fair Fair Year-over-year change in earnings per share Optimal: > 10%	-8.7% Weak Weak Year-over-year change in earnings per share Optimal: > 10%	—	—	—	—	—
Net Income Growth YoY (%)	-1.3% Weak ↑ Weak Improving Year-over-year change in net income	-27.0% Weak ↓ Weak Declining Year-over-year change in net income	-13.0% Weak ↑ Weak Improving Year-over-year change in net income	-13.2% Weak ↑ Weak Improving Year-over-year change in net income	-6.8% Weak ↑ Weak Improving Year-over-year change in net income	-174.2% Weak Weak Year-over-year change in net income	-25.8% Weak Weak Year-over-year change in net income	—	—
FCF Growth YoY (%)	22.1% Good ↑ Good Improving Year-over-year change in free cash flow	2.9% Caution ↑ Caution Improving Year-over-year change in free cash flow	13.6% Fair Fair Year-over-year change in free cash flow	-22.2% Weak Weak Year-over-year change in free cash flow	—	—	—	—	—

💰 Are margins durable? 1 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗
FCF / Net Income (x)	0.86x Caution → Caution Stable Free cash flow relative to reported net income Optimal: > 1x	0.89x Caution ↑ Caution Improving Free cash flow relative to reported net income Optimal: > 1x	0.86x Caution ↑ Caution Improving Free cash flow relative to reported net income Optimal: > 1x	0.87x Caution ↑ Caution Improving Free cash flow relative to reported net income Optimal: > 1x	0.77x Caution ↓ Caution Declining Free cash flow relative to reported net income Optimal: > 1x	0.62x Weak ↓ Weak Declining Free cash flow relative to reported net income Optimal: > 1x	0.90x Caution Caution Free cash flow relative to reported net income Optimal: > 1x	0.99x Caution Caution Free cash flow relative to reported net income Optimal: > 1x	—

🎯 Is capital allocation efficient? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗
Return on Invested Capital (%)	-29.4% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-46.4% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-39.1% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-32.6% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-22.8% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-20.2% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	25.1% Excellent Excellent Return earned on debt + equity capital invested Optimal: > 10%	27.4% Excellent Excellent Return earned on debt + equity capital invested Optimal: > 10%	—
Return on Capital (%) (%)	-35.0% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-52.1% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-44.0% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-37.1% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-26.4% Weak → Weak Stable Operating profit relative to total assets Optimal: > 10%	-24.8% Weak Weak Operating profit relative to total assets Optimal: > 10%	-30.4% Weak Weak Operating profit relative to total assets Optimal: > 10%	—	—
Return on Common Equity (%) (%)	-33.7% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-325%)	-52.6% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-451%)	-44.9% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-400%)	-40.1% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-367%)	-28.8% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-292%)	-25.4% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-270%)	29.8% Excellent Excellent Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+99%)	33.2% Excellent Excellent Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+121%)	—

⚖️ Is the balance sheet risky? 1 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗
Net Debt (USD)	$-45.67M	$-59.41M	$-23.38M	$-66.84M	$-226.01M	$-78.45M	$-89.16M	—	—

📊 What does each share earn? 5 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗
Basic EPS, GAAP (USD)	$-1.47	$-1.83	$-1.96	$-2.25	$-2.07	—	—	—	—
Free Cash Flow per Share (USD)	$-1.27	$-1.63	$-1.68	$-1.95	$-1.59	—	—	—	—
Book Value per Share (USD)	$3.90	$3.42	$4.08	$4.93	$6.92	$7.90	$-45.40	—	—
Tangible Book Value per Share (USD)	$3.90	$3.42	$4.08	$4.93	$6.92	$7.90	$-45.40	—	—
Basic Weighted Avg Shares (shares)	87.79M	69.73M	51.45M	39.66M	37.95M	—	—	—	—

🏦 How resilient is the balance sheet? 2 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗
Working Capital (USD)	$268.05M	$237.40M	$192.14M	$195.07M	$225.37M	$287.69M	$84.64M	—	—
Total Equity (USD)	$384.36M	$243.12M	$224.09M	$222.35M	$272.98M	$289.78M	$-90.08M	$-64.43M	$-43.61M

📋 What is driving earnings? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗
Depreciation Expense (USD)	$1.22M	$1.11M	$1.03M	$966.00K	$897.00K	$970.00K	$1.03M	$903.00K	—
Net Income, GAAP (USD)	$-129.47M	$-127.85M	$-100.70M	$-89.12M	$-78.72M	$-73.70M	$-26.88M	$-21.36M	—
Operating Cash Flow (USD)	$-110.97M	$-112.66M	$-85.69M	$-75.14M	$-59.54M	$-45.27M	$-23.53M	$-20.68M	—

⌨️ Keyboard Shortcuts

/ Search

Esc Clear

A Annual

Q Quarterly

1-7 Jump to category

R Reset

bar_chart Data from SEC EDGAR XBRL filings

Synced 4 days ago 9 years · 32 quarters

Oric Pharmaceuticals, Inc.

Analytical Summary

9-Year Financial Trajectory

Bullish Indicators

Bearish Risks

Health Breakdown

Statement lens

Benchmark Lens

Signals

Percentile Rankings

Peer Comparison

Compare ORIC with peers